BC Advantage - 2023 Issue 10
HHS Selects the First Drugs for Medicare Drug Price Negotiation
Subscribe or sign in to view the full article.
Article Overview
This article explains the first round of Medicare drug price negotiation selected by HHS and CMS under the Inflation Reduction Act. It covers the broader policy context, the timing of negotiations and implementation, the categories of drugs selected, and the program’s future expansion. It is relevant to healthcare policy readers, Medicare stakeholders, pharmacy and benefits professionals, and anyone tracking federal prescription drug pricing changes.
Why This Topic Matters
The announcement marks a major federal step in Medicare prescription drug pricing policy and signals changes that may affect coverage costs, program administration, and stakeholder planning.
What You Will Learn
- The policy context for Medicare drug price negotiation
- How HHS and CMS describe the first selection round
- The announced timing for negotiations and implementation
- The general framework for future Medicare drug selections
- Where to find related federal fact sheets and program information
Who Should Read This
- Medicare stakeholders
- Healthcare policy professionals
- Pharmacy benefit and reimbursement professionals
- Healthcare administrators
- Public health and government affairs readers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com